Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionNomura Asset Management Co Ltd
Latest Disclosed Ownership48,723 shares
Latest Disclosed Value $ 6,418,768
Nomura Asset Management Co Ltd ownership in NBIX / Neurocrine Biosciences, Inc.

On May 11, 2026 - Nomura Asset Management Co Ltd filed a 13F-HR form disclosing ownership of 48,723 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $6,418,768 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 48,723 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 0.00% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 48,723 0 0.00 6,419 -7.12 0.0104
2026-02-10 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 48,723 0 0.00 6,910 1.04 0.0175
2025-11-12 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 48,723 -250 -0.51 6,840 11.11 0.0179
2025-08-11 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 48,973 -8,937 -15.43 6,155 -3.89 0.0169
2025-05-12 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 57,910 4,284 7.99 6,405 -12.50 0.0196
2025-02-12 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 53,626 -2,649 -4.71 7,320 12.88 0.0220
2024-11-15 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 56,275 -1,473 -2.55 6,484 -18.44 0.0200
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 57,748 -5,434 -8.60 7,950 -8.77 0.0271
2024-05-13 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 63,182 -423 -0.67 8,714 3.99 0.0316
2024-02-09 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 63,605 100 0.16 8,381 17.30 0.0346
2023-11-03 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 63,505 -5,580 -8.08 7,144 9.67 0.0335
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 69,085 100 0.14 6,515 -6.70 0.0300
2025-01-10 2023-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 68,985 32,756 90.41 6,983 61.36 0.0367
2023-05-11 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 68,985 32,756 6,983 0.0367
2025-01-10 2022-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 36,229 2,200 6.47 4,327 19.73 0.0251
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 36,229 2,200 4,327 0.0251
2025-01-10 2022-09-30 13F/A-3 NEUROCRINE BIOSCIENCES COM 64125C109 34,029 0 0.00 3,614 8.95 0.0230
2022-11-14 2022-09-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 34,029 0 3,614 0.0230
2022-11-10 2022-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 34,029 0 3,614 0.0230
2022-11-10 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,029 0 3,614 0.0145
2025-01-10 2022-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 34,029 2,100 6.58 3,317 10.83 0.0207
2022-08-12 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 34,029 2,100 3,317 0.0205
2025-01-10 2022-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 31,929 0 0.00 2,993 10.08 0.0163
2022-05-13 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 31,929 0 2,993 0.0163
2025-01-10 2021-12-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 31,929 13,529 73.53 2,719 54.14 0.0137
2022-02-01 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 31,929 13,529 2,719 0.0137
2025-01-10 2021-09-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 18,400 -13,209 -41.79 1,765 -42.65 0.0100
2021-11-12 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 18,400 -13,209 1,765 0.0100
2025-01-10 2021-06-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 31,609 1,327 4.38 3,076 4.48 0.0178
2021-08-06 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 31,609 1,327 3,077 0.0178
2025-01-10 2021-03-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 30,282 -1,082 -3.45 2,945 -2.06 0.0188
2021-05-14 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 30,282 -1,082 2,945 0.0188
2025-01-10 2020-12-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 31,364 429 1.39 3,006 1.04 0.0202
2021-02-12 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 31,364 429 3,006 0.0202
2020-11-12 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 30,935 0 0.00 2,975 -21.19 0.0228
2020-08-13 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 30,935 1,304 4.40 3,775 47.17 0.0319
2020-05-14 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 29,631 1,400 4.96 2,565 -15.49 0.0265
2020-02-13 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 28,231 13,620 93.22 3,035 130.45 0.0272
2019-11-13 2019-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 1,317 6.73 0.0126
2019-08-13 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 1,234 -4.12 0.0122
2019-05-10 2019-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 1,287 23.39 0.0126
2019-05-10 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 1,287
2019-02-12 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 1,043 -41.93 0.0117
2018-11-07 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 1,796 25.16 0.0174
2018-08-03 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 1,435 18.40 0.0149
2018-05-14 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 1,212 6.88 0.0132
2018-02-14 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 1,134 26.70 0.0131
2017-11-13 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 895 33.18 0.0116
2017-08-14 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 672 6.16 0.0090
2017-06-28 2017-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 633 12.04 0.0089
2017-05-12 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 633
2017-02-14 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 565 -23.65 0.0102
2016-11-10 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 0 0.00 740 11.45 0.0133
2016-08-12 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 14,611 -7,281 -33.26 664 -23.33 0.0124
2016-05-13 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 21,892 21,892 0.00 866 0.0165
2016-02-12 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 0 0 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.